Perbio Science year-end report
Perbio Science year-end report A successful 2001 · Net sales up 35% to SEK 1 899 (1 409) million · Continued strong earnings growth at all divisions - Operating profit before amortisation of goodwill up 78% to SEK 348 (196) million - Profit after financial items but before amortisation of goodwill up 99% to SEK 339 (170) million - Profit after financial items up 112% to SEK 318 (150) million - Net profit up 114% to SEK 193 (90) million · Bioresearch division: *- New test for mad cow disease (BSE) developed together with Prionics AG - Sales of amidites (reagents for DNA synthesis) taken over from Amersham Biosciences · Cell Culture division: - Investment in new plant to double cell culture media production capacity - Joint venture company HyNetics set up with Kinetics Group to market new production method for media and sterile liquids · Medical Device division: - HME (heat & moisture exchanger) product group gains reimbursement status in the USA "Perbio Science recorded net sales of SEK 503 million and net profit of SEK 50 million in the fourth quarter," says CEO Mats Fischier. "Our operating margin for the year as a whole was 4.7 percentage points up on 2000 at 17.2%. "Besides achieving strong earnings growth, Perbio continued to increase its share of the US market, launched more new products than in previous years and entered into a number of interesting alliances with customers and suppliers." FURTHER INFORMATION CEO Mats Fischier tel +46 42 26 90 91 or +46 70 595 18 21 CFO Claes Wenthzel tel +46 42 26 90 92 or +46 70 862 01 22 More information on Perbio Science can also be found on our website at www.perbio.com. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2002/02/12/20020212BIT00290/bit0001.doc http://www.waymaker.net/bitonline/2002/02/12/20020212BIT00290/bit0001.pdf